Description: Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Home Page: www.novavax.com
NVAX Technical Analysis
21 Firstfield Road
Gaithersburg,
MD
20878
United States
Phone:
240 268 2000
Officers
| Name | Title |
|---|---|
| Mr. Stanley Charles Erck | Pres, CEO & Director |
| Mr. James Patrick Kelly C.F.A. | Exec. VP, CFO & Treasurer |
| Mr. John A. Herrmann III | Exec. VP, Chief Legal Officer & Corp. Sec. |
| Mr. John Joseph Trizzino B.S., M.B.A. | Exec. VP and Chief Bus. & Commercial Officer |
| Dr. Gregory M. Glenn | Pres of R&D |
| Mr. Richard P. Crowley | Exec. VP & COO |
| Dr. Gale E. Smith | Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist |
| Mr. Biegie Lee | Sr. VP & Chief Information Officer |
| Mr. Troy Morgan Esq., J.D. | Sr. VP & Chief Compliance Officer |
| Ms. Erika S. Trahan | Associate Director of Investor & PR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0.5781 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 49.522 |
| Price-to-Sales TTM: | 0.4812 |
| IPO Date: | 1995-12-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 1541 |